Verona Pharma Initiates Phase 2 Clinical Trial with Metered Dose Inhaler Formulation of Ensifentrine for Maintenance Treatment of COPD

Ensifentrine delivery via MDI inhalers could dramatically expand clinical utility and commercial opportunity

LONDON, June 04, 2019 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces the initiation of a Phase 2 dose-ranging trial to evaluate the pharmacokinetic (“PK”) profile, efficacy and safety of a pressurized metered-dose inhaler (“MDI”) formulation of ensifentrine (RPL554) in patients with moderate-to-severe chronic obstructive pulmonary disease (“COPD”). Verona Pharma is also developing a dry powder inhaler (“DPI”) formulation of ensifentrine.

In the US, DPI/MDI handheld inhalers are the most widely used option for medication in COPD, where an estimated 5.5 million people use inhalers for COPD maintenance therapy.1 This market was valued at approximately $6 billion in 2017.2

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH